Cleared Traditional

K770902 - COLORIMETRIC DETERM. SOCITRATE DEHYDRO. (FDA 510(k) Clearance)

Class I Chemistry device.

K770902 · Sigma Chemical Co. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1977
Decision
59d
Days
Class 1
Risk

K770902 is an FDA 510(k) clearance for the COLORIMETRIC DETERM. SOCITRATE DEHYDRO.. Classified as Hydrazone Deriv. Of Alpha-ketogluterate (colorimetry), Isocitric Dehydrogen (product code JKH), Class I - General Controls.

Submitted by Sigma Chemical Co. (Mchenry, US). The FDA issued a Cleared decision on July 14, 1977 after a review of 59 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1420 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Sigma Chemical Co. devices

Submission Details

510(k) Number K770902 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 16, 1977
Decision Date July 14, 1977
Days to Decision 59 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
29d faster than avg
Panel avg: 88d · This submission: 59d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code JKH Hydrazone Deriv. Of Alpha-ketogluterate (colorimetry), Isocitric Dehydrogen
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.1420
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.